Gene delivery to the vasculature mediated by low-titre adeno-associated virus serotypes 1 and 5

Journal of Gene Medicine

Volumn 10, Issue 2, 2008, Pages 143-151

  Sen, S ^a,b,e   Conroy, S ^a,b   Hynes, S O ^a,b   McMahon, J ^a,b   O'Doherty, A ^a,b   Bartlett, J S ^c   Akhtar, Y ^b   Adegbola, T ^b   Connolly, C E ^b   Sultan, S ^b   Barry, F ^a   Katusic, Z S ^d   O'Brien, Timothy ^a,b  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b UNIVERSITY HOSPITAL GALWAY   (Ireland)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d MAYO CLINIC   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

AAV serotypes; Cardiovascular; Gene transfer

Indexed keywords

BETA GALACTOSIDASE; DEOXYRIBONUCLEASE; ENHANCED GREEN FLUORESCENT PROTEIN; PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADVENTITIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; COMMON CAROTID ARTERY; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; IN VIVO GENE TRANSFER; NONHUMAN; PRIORITY JOURNAL; RABBIT; SEROTYPE; SMOOTH MUSCLE FIBER; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS TITRATION;

ANIMALS; BETA-GALACTOSIDASE; CAROTID ARTERIES; CELLS, CULTURED; DEPENDOVIRUS; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; GREEN FLUORESCENT PROTEINS; HUMANS; MYOCYTES, SMOOTH MUSCLE; RABBITS; SEROTYPING; TRANSDUCTION, GENETIC; TRANSGENES;

ADENO-ASSOCIATED VIRUS; ORYCTOLAGUS CUNICULUS;

EID: 39449101529     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1133     Document Type: Article

References (33)

1. Melo LG, Pachori AS, Gnecchi M, et al. Genetic therapies for cardiovascular diseases. Trends Mol Med 2005; 11: 240-250.
2. Baker AH. Designing gene delivery vectors for cardiovascular gene therapy. Prog Biophys Mol Biol 2004; 84: 279-299.
3. Yla-Herttuala S, Alitalo K. Gene transfer as a tool to induce therapeutic vascular growth. Nat Med 2003; 9: 694-701.
4. Monahan PE, Samulski RJ. Adeno-associated virus vectors for gene therapy: more pros than cons? Mol Med Today 2000; 6: 433-440.
5. Flotte TR. Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors. Gene Ther 2004; 11: 805-810.
6. Rabinowitz JE, Bowles DE, Faust SM, et al. Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups. J Virol 2004; 78: 4421-4432.
7. Summerford. C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 72: 1438-1445.
8. Summerford C, Bartlett JS, Samulski RJ. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 1999; 5: 78-82.
9. Walters RW, Yi SM, Keshavjee S, et al. Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem 2001; 276: 20610-20616.
10. Hauck B, Xiao W. Characterization of tissue tropism determinants of adeno-associated virus type 1. J Virol 2003; 77:2768-2774.
11. Nicklin SA, Buening H, Dishart KL, et al. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol Ther 2001; 4: 174-181.
12. Wang Z, Zhu T, Qiao C, et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 2005; 23: 321-328.
13. Davidoff AM, Gray JT, Ng CY, et al. Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol Ther 2005; 11: 875-888.
14. Richter M, Iwata A, Nyhuis J, et al. Adeno-associated virus vector transduction of vascular smooth muscle cells in vivo. Physiol Genomics 2000; 2: 117-127.
15. Rolling F, Nong Z, Pisvin S, et al. Adeno-associated virus-mediated gene transfer into rat carotid arteries. Gene Ther 1997; 4: 757-761.
16. Denby L, Nicklin SA, Baker AH. Adeno-associated virus (AAV)-7 and -8 poorly transduce vascular endothelial cells and are sensitive to proteasomal degradation. Gene Ther 2005; 12: 1534-1538.
17. Chen S, Kapturczak M, Loiter SA, et al. Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors. Hum Gene Ther 2005; 16: 235-247.
18. Dishart KL, Denby L, George SJ, et al. Third-generation lentivirus vectors efficiently transduce and phenotypically modify vascular cells: implications for gene therapy. J Mol Cell Cardiol 2003; 35: 739-748.
19. Grimm D, Kay MA, Kleinschmidt JA. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther 2003; 7: 839-850.
20. Veldwijk MR, Topaly J, Laufs S, et al. Development and optimization of a real-time quantitative PCR-based method for the titration of AAV-2 vector stocks. Mol Ther 2002; 6: 272-278.
21. Sharif F, Hynes SO, McMahon J, et al. Gene-eluting stents: comparison of adenoviral and adeno-associated viral gene delivery to the blood vessel wall in vivo. Hum Gene Ther 2006; 17: 741-750.
22. Pajusola K, Gruchala M, Joch H, et al. Cell-type-specific characteristics modulate the transduction efficiency of adeno-associated virus type 2 and restrain infection of endothelial cells. J Virol 2002; 76: 11530-11540.
23. Ding W, Yan Z, Zak R, et al. Second-strand genome conversion of adeno-associated virus type 2 (AAV-2) and AAV-5 is not rate limiting following apical infection of polarized human airway epithelia. J Virol 2003; 77: 7361-7366.
24. Sanlioglu S, Monick MM, Luleci G, et al. Rate limiting steps of AAV transduction and implications for human gene therapy. Curr Gene Ther 2001; 1: 137-147.
25. Ferrari FK, Samulski T, Shenk T, et al. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996; 70: 3227-3234.
26. Lynch CM, Hara PS, Leonard JC, et al. Adeno-associated virus vectors for vascular gene delivery. Circ Res 1997; 80: 497-505.
27. Maeda Y, Ikeda U, Ogasawara Y, et al. Gene transfer into vascular cells using adeno-associated virus (AAV) vectors. Cardiovasc Res 1997; 35: 514-521.
28. Al-Dosari M, Zhang G, Knapp JE, et al. Evaluation of viral and mammalian promoters for driving transgene expression in mouse liver. Biochem Biophys Res Commun 2006; 339: 673-678.
29. Gruchala M, Bhardwaj S, Pajusola K, et al. Gene transfer into rabbit arteries with adeno-associated virus and adenovirus vectors. J Gene Med 2004; 6: 545-554.
30. Nitta Y, Kawamoto S, Halbert C, et al. A CMV-actin-globin hybrid promoter improves adeno-associated viral vector gene expression in the arterial wall in vivo. J Gene Med 2005; 7: 1348-1355.
31. Reinhardt B, Mertens T, Mayr-Beyrle U, et al. HCMV infection of human vascular smooth muscle cells leads to enhanced expression of functionally intact PDGF beta-receptor. Cardiovasc Res 2005; 67: 151-160.
32. Masaki I, Yonemitsu Y, Komori K, et al. Recombinant Sendai virus-mediated gene transfer to vasculature: a new class of efficient gene transfer vector to the vascular system. FASEB J 2001; 15: 1294-1296.
33. Rome JJ, Shayani V, Flugelman MY, et al. Anatomic barriers influence the distribution of in vivo gene transfer into the arterial wall. Modeling with microscopic tracer particles and verification with a recombinant adenoviral vector. Arterioscler Thromb 1994; 14: 148-161.